An Immunoinformatics Approach To Identify Immunogenic Peptide Of Hemagglutinin Protein In H1N1 Virus | 4884
Journal of Biotechnology & Biomaterials
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Influenza virus, which has been frequently associated with human respiratory infections, poses potential threat of widespread
pandemics. The most recent outbreaks of Influenza in 2009 was the outcome of triple reassorted H1N1 called swine-origin
influenza virus (S-OIV)A/H1N1. In view of the compelling need of a vaccine which is crossreactive against all the existing
and eventually appearing strains of H1N1, various efforts have been made to identify conserved epitope as vaccine target. In
our study, first we have predicted conserved peptide sequences of hemagglutinin (HA) obtained from all the reported strains
of H1N1 using MUSCLE and AVANA tool. Three different epitope prediction tools were used for each Class I and II MHC
separately. BLAST screening was employed to eliminate the peptides bearing homology with human proteome. Six out of twenty
four epitopes predicted to binding class I HLA and two out of twelve epitopes predicted for Class II HLA were eliminated after
BLAST analysis. Finally, ten conserved peptides containing overlapping epitopes for class I MHC and five peptides containing
overlapping epitopes for class II MHC were generated. Owing to the extensive polymorphic nature of HLA alleles, population
coverage analysis (tool by IEDB) was carried out for the resultant epitopes in the conserved peptides. The predicted average
population coverage for class I and class II conserved peptide was 86.36% and 36% respectively. Thus, using immunoinformatics
tools, we were able to select the peptide containing overlapping epitopes which may be considered as probable vaccine candidates.
Manoj Baranwal has done M.Sc from JNU, New Delhi. After that he has completed his PhD in clinical and cellular immunology from Duisburg-Essen
University, Germany and continues his postdoc for one year there. He is presently working as assistant professor in Department of biotech & Env
Sciences, Thapar University Patiala. He is working on Epitope Based Vaccine design in Influenza Virus (Immunoinformatics based and experimental
validation) and Screening of bioactive molecules from endophytic fungi for anticancer activity; Immunomodulatory and Immunosuppressive activity.
He has published four international papers in reputed journals and attended several conferences.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals